CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SEMAGLUTIDE LONG-ACTING INJECTION (SYH9017) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Semaglutide Long-acting Injection (SYH9017) (the "**Product**"), a GLP-1 receptor agonist developed by the Group, has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S.

The Product is a once-monthly semaglutide preparation independently developed by the Group. Utilising the Group's long-acting delivery technology platform and excipients with good biocompatibility, the Product is injected subcutaneously to form a gel depot that enables long-acting drug delivery. Compared with the once-weekly semaglutide injection on the market, the Product is expected to extend dosing to once per month, significantly improving patient medication adherence and possessing distinct clinical advantages. Domestic clinical studies demonstrated that compared with the semaglutide injection on the market, the Product had comparable weight loss efficacy, favorable safety profile and significantly prolonged half-life, supporting clinical development of the once-monthly preparation.

The indication for this clinical trial approval is weight management in adults who are overweight or obese, along with a reduced-calorie diet and increased physical activity. In addition, the Product has the potential for the treatment of type 2 diabetes and reduction of cardiovascular disease risk, providing a promising clinical development value. The Product represents the Group's first long-acting once-monthly preparation of GLP-1. The clinical trial approval in the U.S. lays a solid foundation for the development of more innovative products in the future.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 8 June 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.